Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

A new experimental drug, Nerandomilast, has shown potential in reducing lung inflammation and fibrosis in preclinical models of Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease ...

In people destined to get Alzheimer's in their mid-40s, one protein can delay the onset of the disease by about 20 years.

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...

Explore how proteomics enables personalized medicine by improving patient stratification, treatment response, and diagnostics ...

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

Eighty-five original research projects from aspiring physician-scientists were on display at the 2026 Medical Student Research Forum at the Jacobs School of Medicine and Biomedical Sciences.

Researchers identified a critical AMPK phosphorylation site that regulates mitochondria, muscle contraction, and sugar ...

Let’s say it’s 2036, and scientists are working on a new class of drugs. These medications are mirror-image versions of the molecules your body uses to fight disease. Their big advantage is that ...

The discovery that tissues use electricity to expel unhealthy cells is part of a surge of renewed interest in the currents flowing through our bodies. We’re used to thinking of the brain as an ...